Influence of Preoperative Immunomodulation by Oral Impact on Postoperative Complications F
any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay.
| Condition(s) | Urological Manifestations |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | any studies have shown the benefit of perioperative Oral Impact immunomodulation in gastrointestinal, ENT, gynecological and cardiac surgery. Studies in major Urological surgery are rare and not very contributory. The expected benefit is a reduction in postoperative complications and the average length of stay. |
| Who can participate | Inclusion Criteria: * 18 years of age and older * Scheduled major urological surgery: scheduled: cystectomy, nephrectomy, other laparotomies. * Having expressed their free and informed consent. * Affiliated to a social security scheme Exclusion Criteria: * Immune deficiency. * HIV infection. * Curative surgery for chronic urinary tract infection. * Urgent surgery. * Inability to take oral impact 7 days before surgery. * Unstable psychiatric state. * Infection with COVID 19 during postoperative stay. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier Intercommunal Robert Ballanger |
| Locations | Aulnay-sous-Bois, France; Montreuil, France |
| Start date | 2022-11-30 |
| NCT ID | NCT05520151 |
| Official listing | https://clinicaltrials.gov/study/NCT05520151 |